Can a TB vaccine be upgraded to fight RSV in seniors?
NCT ID NCT07762014
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This trial is testing a new vaccine called rBCG-N-RSV, which is based on the BCG vaccine (used for tuberculosis) but modified to also target respiratory syncytial virus (RSV). The study involves 200 adults over 60 years old, who will receive either this new vaccine or the standard BCG vaccine. The goal is to see if the new vaccine is safe and whether it triggers a stronger immune response against both TB and RSV compared to the standard BCG.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A recombinant BCG vaccine that also expresses the RSV nucleoprotein (rBCG-N-RSV)
- What this could lead to
- If successful, this could lead to a single vaccine that protects older adults against both RSV and tuberculosis, potentially reducing severe respiratory infections.
- What could go wrong
- This is an early-phase trial focused on safety and immune response, not yet on preventing disease. The vaccine may not produce a strong enough immune response or could cause side effects like injection-site reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTION PREVENTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sotiria Thoracic Diseases Hospital of Athens
Athens, Greece
More trials for these conditions
Other studies related to the condition(s) this trial covers.